Happy Father's Day: New Investments in Biotech, Wellness, and Beverages

In partnership with

Nectar is a modern Asian alcohol company that offers a unique hard seltzer product. They have launched a campaign on Wefunder to raise $1,200,000, already raising $518,376. The minimum investment is $200. Nectar has seen significant success in the market, being the top-selling new hard seltzer in Ralphs and achieving notable ranks in other major retailers like Fred Meyer, HEB, Total Wine, and Safeway.

Highlights

• VC-Backed: Raised over $250,000 from a venture firm.

• Revenue: Over $5 million earned in the last 12 months.

• Market Penetration: Top ranks in new and existing retailers.

• Community: Over 1,700,000 members.

• Growth: 120% average year-over-year growth since 2021.

Featured Investors

• Goat Rodeo Capital: Invested $2,975,000. Known for successful partnerships in the alcohol industry.

• Lora Larson-Miller: Invested $5,000. Enthusiastic about unique beverage brands and authentic flavors.

Team

• Jeremy Kim: Co-founder and CEO. Background in the music industry and digital marketing.

• John Dalsey: Co-founder and President. Experience in the craft beer industry.

• Brando Brando: Co-founder and Art Director. Expertise in design and visual arts.

Additional Information

Nectar offers various investor perks, ranging from $250 to $250,000, depending on the investment amount. The company emphasizes unique flavors and engaging content, setting them apart in the competitive drinks industry.

For more details, you can visit their official website.

Unique Investment Opportunity: Whiskey Casks

Here’s an investment opportunity you didn’t know you were missing - whiskey casks.

But where to start?

Try Vinovest.

Vinovest differentiates its whiskey investing platform through strategic sourcing and market analysis. With Vinovest, you can invest in Scotch, American, and Irish whiskey casks, providing diverse and flexible exit options.

Vinovest team targets high-growth markets and caters to a range of buyers, from collectors to brands using casks for cocktails. This approach not only enhances your liquidity but also increases your portfolio’s resilience against market fluctuations. Discover how Vinovest’s innovative strategy sets it apart from competitors.

Schedule a call with a Vinovest advisor to learn more.

Opportunity in Biotech: Phormed's Groundbreaking Campaign on Wefunder

Invest in the Future of Medicine

Phormed, a trailblazer in the biotech industry, is on a mission to transform the landscape of medical treatments for cancer, inflammation, and other severe diseases. This innovative company is now offering a unique pre-public investment opportunity on Wefunder, and you can be part of this revolutionary journey.

Why Phormed Stands Out

Phormed’s cutting-edge technology aims to repair damaged cells and eradicate cancer cells, providing hope for patients battling life-threatening conditions. Their platform drug, RP323, is designed to target a range of severe diseases, including acute myeloid leukemia (AML), Hodgkin's lymphoma, Parkinson's disease, and acute respiratory distress syndrome (ARDS).

The company’s groundbreaking approach has caught the medical community's attention and attracted substantial investor interest. With $3.5 million already raised from over 4,100 investors, Phormed is well on its way to revolutionizing healthcare.

Investment Highlights

• FDA Fast-Track Approval: The FDA has fast-tracked Phormed’s innovative technology for phase 1 and phase 2 clinical trials, underscoring its potential and safety.

• Significant Market Potential: Positioned as a highly undervalued company, Phormed has a pre-money valuation of $53 million, with similar companies valued between $290 million and $1.2 billion.

• Proven Success: Early clinical trials have demonstrated remarkable results, including an 83% success rate in AML remission and significant tumor reduction in Hodgkin's lymphoma.

Meet the Visionary Team

Led by CEO Ben Chang, who brings over 30 years of pharmaceutical and executive-level experience, Phormed boasts a team of seasoned professionals. Prof. Richard L. Chang, the inventive force behind RP323, has authored 122 peer-reviewed journal publications and holds nine patents. Carole A. Salvador, PsyD, brings over three decades of experience in psychology and biochemistry research to her role as Secretary/Treasurer and HR Director.

Join the Movement

Investing in Phormed is more than a financial decision; it’s a commitment to advancing medical science and offering new hope to millions of patients. With a minimum investment of just $250, you can be part of this revolutionary effort to change the face of medicine. Early bird investors will also receive a 10% bonus on shares, making it an even more attractive opportunity.

Seize the chance to support groundbreaking innovation in healthcare. Visit Phormed's Campaign on Wefunder to learn more and invest today.

Spotlight 🔦:

Sensate is revolutionizing stress relief with its innovative, research-backed device that uses infrasonic resonance to quickly reduce stress by stimulating the vagus nerve. Launched in 2019, Sensate has generated over $15 million in revenue, achieving 100% year-over-year growth, and offers a subscription service for guided relaxation. Available in over 50 countries, the device significantly reduces stress in minutes, making it an attractive option for busy individuals. With strong market traction, financial performance, and growth potential, Sensate presents a compelling investment opportunity as it aims to expand its product range and global reach in the booming wellness market.

Read More:

Last Issues Poll Results 🗳️:

Would You Invest In Holme & Hadfield?

🟩🟩🟩🟩🟩🟩 👍 (52)

🟨🟨🟨🟨🟨⬜️ 👎 (46)

🟨🟨🟨🟨🟨⬜️ 🤷 (46)

144 Votes

Would You Invest In Bracketology?

🟩🟩🟩🟩🟩🟩 👍 (48)

🟨🟨🟨🟨🟨⬜️ 👎 (42)

🟨🟨🟨🟨🟨⬜️ 🤷 (44)

134 Votes